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Background: Epigenetic modifications play a critical role in the regulation of all DNA-based processes, such as
transcription, repair, and replication. Inappropriate histone modifications can result in dysregulation of cell growth,
leading to neoplastic transformation and cell death. Renal tumors have been shown to have a higher global
methylation percentage and reduced histone acetylation. Preclinical models have revealed that histone gene modifiers
and epigenetic alterations play important roles in renal cell carcinoma (RCC) tumorigenesis. Recently, a novel HDAC
inhibitor, N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), has been introduced as an example of a new class of
anti-cancer agents. The anti-cancer activity of HNHA and the underlying mechanisms of action remain to be clarified.
Methods: The MTS assay using a panel of RCC cells was used to evaluate the anti-proliferative effects of HNHA. The
established HDAC inhibitors, SAHA and TSA, were used for comparison. Western blotting analysis was performed to
investigate the acetylation of histone H3 and the expression of apoptotic markers in vitro and in vivo. Subcellular
fractionation was performed to evaluate expression of Bax and cytochrome c in the cytosol and mitochondria, and also
translocation of cytochrome c from the cytoplasm to the nucleus. A confocal microscopic evaluation was performed to
confirm inhibition of cell proliferation, induction of apoptosis, and the nuclear translocation of cytochrome c in RCC
cells.
Results: In this study, we investigated the apoptosis-inducing activity of HNHA in cultured kidney cancer cells.
Apoptosis in the HNHA-treated group was induced significantly, with marked caspase activation and Bcl-2 suppression
in RCC cells in vitro and in vivo. HNHA treatment caused cytochrome c release from mitochondria, which was mediated
by increased Bax expression and caspase activation. HNHA also induced nuclear translocation of cytochrome c,
suggesting that HNHA can induce caspase-independent nuclear apoptosis in RCC cells. An in vivo study showed that
HNHA had greater anti-tumor and pro-apoptotic effects on RCC xenografts than the established HDAC inhibitors.
Conclusions: HNHA has more potent anti-tumor activity than established HDAC inhibitors. Its activities are mediated
by caspase-dependent and cytochrome-c-mediated apoptosis in RCC cells. These results suggest that HNHA may offer
a new therapeutic approach to RCC.
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The initiation and progression of cancer, traditionally
seen as a genetic disease, is now known to involve epi-
genetic abnormalities along with genetic alterations [1].
Epigenetic modifications, defined as heritable changes in
gene expression that are not due to any alteration in the
DNA sequence, play a key role in the regulation of all
DNA-based processes, such as transcription, repair, and
replication [2]. Consequently, abnormal expression pat-
terns or genomic alterations in chromatin regulators
have profound results and can lead to the development
and maintenance of various cancer types [3].
One epigenetic modification common in several tumors
is the modification of histones. Histones are the chief pro-
tein components of chromatin, acting not simply as spools
around which DNA is coiled, but also as regulators of
chromatin dynamics [4]. Because histone modifications
are proposed to affect chromosome function, inappropri-
ate histone modifications would be expected to result in
dysregulation of cell growth, leading to neoplastic trans-
formation or cell death [3-6]. The histone-modifying en-
zymes, histone acetyltransferases—which include histone
deacetylases (HDACs) and histone methyltransferases
(HMTs)—regulate these modification processes.
HDACs are important regulators of gene expression
that remove acetyl groups from histones enzymatically.
Numerous studies have demonstrated aberrant expres-
sion of HDACs in human tumors, and the expression
levels of HDAC1, −5, and −7 serve as molecular bio-
markers of tumor versus normal tissue. Moreover, in sev-
eral cancer types, overexpression of individual HDACs
correlates with significant decreases in both disease-free
and overall survival [7-11]. Recent studies revealed that
HDAC plays an important role in carcinogenesis and the
overexpression of HDACs has been linked to key events in
the repression of the tumor suppressor gene CDKN1A,
encoding p21, and genes encoding DNA damage repair
enzymes, such as BRCA1 and ATR [12].
Renal cell carcinoma (RCC) is a malignancy of the kid-
ney that originates in the proximal renal tubule and
accounts for ~3% of all cancers [13]. Although the inci-
dence of small renal masses is high, approximately one
in three patients presents with metastatic disease [14].
RCC is highly resistant to chemotherapy and radiother-
apy; non-specific immunotherapy using interleukins and
interferons are used as a standard treatment; however,
the response rate is low.
Recent clarification of the molecular mechanisms of
RCC has permitted tremendous progress in the develop-
ment and approval of multiple targeted agents for the
treatment of advanced RCC. Therapies targeted at the
“vascular endothelial growth factor” (VEGF) and “mam-
malian target of rapamycin” (mTOR) pathways now rep-
resent the standard of care in metastatic RCC [13,14].However, durable therapeutic responses to these therapies
are uncommon, and the prognosis of RCC remains
dismal.
Recent molecular investigations revealed that RCC has
a higher percentage of global methylation and reduced
histone acetylation, compared with non-tumor counter-
part cells [15]. Several studies have demonstrated that
histone deacetylases are highly expressed and decreased
acetylation of histone H3 is a common alteration in
RCC [16,17].
The use of massively parallel sequencing technologies
enabled the discovery of additional common epigenetic
modifications. Preclinical models have revealed that his-
tone gene modifiers and epigenetic alterations may play
important roles in RCC tumorigenesis and progression.
In vitro analyses of renal tumor cell lines treated with
vorinostat or ritonavir, alone and in combination, showed
consistent dephosphorylation of Rb along with reduced
HDAC1 expression and an increase in the sub-G1 fraction
with combination treatment [18].
The biological outcome of HDAC inhibition is depe-
ndent on the HDAC specificity of the compound and the
intrinsic operation of the cell-signaling pathways. Recently,
N-hydroxy-7-(2-naphthylthio) hepatonomide (HNHA)
has been introduced. It is a novel HDAC inhibitor that
potently suppresses histone hypoacetylation and down-
regulation of HDAC target genes [19]. In this first study
introducing HNHA, HNHA exhibited potent HDAC-
inhibitory activity with IC50 values of 0.1 lM. In contrast,
other compounds containing substituted nitrogen or
oxygen for sulfur atom and having different lengths of
alkyl chain (C5 and C7) showed weaker activity than
that of HNHA. Moreover, compounds containing differ-
ent zinc-chelating motifs such as an aminophenyl group
or a hydroxy-acetylamino group had a weaker HDAC-
inhibitory activity [19]. HNHA shows strong anti-cancer
activity with pharmacological properties superior to
those of the known HDAC inhibitor SAHA in human fibro-
sarcoma and breast cancer cells [19,20]. Here, we investi-
gated this novel HDAC inhibitor and its mitochondrion-
targeted actions in RCC and discuss the role of HNHA in
induction of apoptotic cell death pathways in RCC.
Methods
Cell culture
The human RCC cell lines Caki-1 and A-498 were ob-
tained from the American Type Culture Collection and
maintained in McCoy’s 5A medium (Hyclone, Thermo
Fisher Scientific), supplemented with 10% fetal bovine
serum (FBS) and in minimal essential medium (MEM;
Invitrogen), supplemented with 10% FBS and 2 mM
L-glutamine. Cells were cultured at 37°C in a humidi-
fied atmosphere with 5% CO2. For all experiments, cell
lines were maintained for no more than 2 months.
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Cell proliferation was measured using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay. Cells were seeded in 96-well plates at 5 × 103 per
well and incubated overnight to 70% confluency. Drug
was added at 0-120 μM final concentrations. After drug
treatment, cells were incubated for 0, 12, 24, 36, 48, 60,
and 72 h and cell viability was then measured using the
MTT reagent at 490 nm according to the manufacturer’s
protocol. Briefly, MTT reagent (10 μL) was added to
each well (final concentration, 0.5 mg/mL) and the plate
was incubated at 37°C. After 4 h, 100 μL of solubiliza-
tion solution (10% SDS) were added to each well and the
plate was incubated for 2 h. Data are presented as mean
percentages of vehicle-treated cell proliferation ± SEM of
triplicate experiments.
TUNEL assay
To assay apoptosis, cells were fixed with 4% paraformalde-
hyde after 48 h of treatment and stained using a terminal
deoxynucleotidyl transferase dUTP nick-end labeling
(TUNEL) kit (Promega, Madison, WI). Apoptotic (fluores-
cent green) and total cells were counted under a fluores-
cence microscope and data were recorded. Images were
obtained using a confocal microscope (LSM Meta 700, Carl
Zeiss, Oberkochen, Germany) and analyzed using the Zeiss
LSM Image Browser software (ver. 4.2.0121).
Cellular fractionation
To assess cytochrome c release, cells were incubated
with 0.05% digitonin in an isotonic sucrose buffer
(250 mM sucrose, 10 mM HEPES-NaOH, 10 mM KCl,
1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, andCaki-1
A
B
Figure 1 HNHA induced acetylation of histone H3 in RCC cells. Caki-1
(A). Caki-1 and A-498 were treated with HNHA (15 μM) for 1, 6, 24, 48, or 7
acetylation was evaluated by Western blotting.0.5 mM phenylmethylsulfonyl fluoride; pH 7.2) at room
temperature. At this concentration, digitonin permeabi-
lizes the plasma membrane but not the mitochondrial
membrane. The digitonin extract was collected as the
cytosolic fraction for immunoblot analysis. To examine
Drp1 translocation to mitochondria during apoptosis, cells
were collected in ice-cold isotonic sucrose buffer by gentle
scraping and homogenized using a Wheaton homogenizer.
The homogenate was centrifuged (1000 g) to remove deb-
ris and nuclei; the supernatant was subjected to a further
centrifugation step (10,000 g) to yield the mitochondrial
fraction. All homogenization and centrifugation proce-
dures were conducted at 4°C.
Western blotting analysis
Cells were washed twice with cold phosphate-buffered
saline and lysed on ice with RIPA buffer (Thermo Fisher
Scientific, Suwanee, GA, USA) following the manufac-
turer’s protocol. Protein concentrations were determined
by BCA assay (Pierce Biotechnology, Rockford, IL).
Equal amounts of protein (20 μg) were separated in 8-10%
SDS-polyacrylamide gels; the resolved proteins were then
electro-transferred onto PVDF membranes (Millipore,
Bedford, MA). The membranes were subsequently blocked
with 5% nonfat milk in TBST for 1 h at room temperature
and incubated with appropriate concentrations of primary
antibodies—acetyl-histone H3 and histone H3 (Abcam,
Cambridge, UK), acetyl-α-tubulin and α-tubulin (Abcam),
Bax (Novus Biologicals, Littleton, CO, USA), p53 (Abcam),
p21 (Abcam), Apaf-1 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), CDK-4 (Cell Signaling Technology,
Beverly, MA, USA), CDK-6 (Cell Signaling Technology),
cyclin D1(Cell Signaling Technology), caspase-3 (SantaA-498 
and A-498 cells were treated for 24 h with 0.1, 1, 10, or 20 μM HNHA
2 h (B). Total proteins were isolated and histone H3 and α-tubulin
Park et al. BMC Cancer  (2015) 15:19 Page 4 of 12Cruz), caspase-7 (Santa Cruz), Bcl-2 (Santa Cruz), p-IκB
(Abcam), cytochrome c (Abcam), and β-actin (Santa Cruz)
—overnight at 4°C. The membranes were then washed
three times with TBST and probed with the corresponding
secondary antibodies conjugated to HRP (Santa Cruz) at
room temperature for 1 h. After washing, blots were devel-
oped with ECL reagents (Pierce, Rockford, US) and exposed
to Kodak X-OMAT AR Film (Eastman Kodak, Rochester,
US) for 3 min.Human kidney cancer cell xenograft
Animals were maintained under specific pathogen-free
(SPF) conditions. All experiments were approved by the
Animal Experiment Committee of Yonsei University.
Human kidney cancer cells (1.0 × 107/mouse) were cul-
tured in vitro and injected subcutaneously into the upper
left flank region of the mice. The mice were maintained at
22°C with a 12/12-h light/dark cycle and access to food and
water ad libitum. After 10 days, tumor-bearing mice were
grouped randomly (n = 10/group) and an intraperitonealA
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Figure 2 HNHA suppressed RCC tumor cell proliferation. Cell viability a
inhibition of tumor cell proliferation in Caki-1 (A-C) and A-498 cells (D-F) P
(B, E) experiments were repeated at least three times with similar results. *injection of the three drugs (SAHA, TSA, and HNHA) was
administered once every 2 days for a total of six injections
(30 mg/kg per mouse) when the complete tumor size
reached [4/3 × π × (0.7 × 0.4 cm)3 × ½]. Tumor size was
measured every other day using calipers. Tumor volume
was estimated using the following formula 4/3 × π × (a
cm× b cm)3 ×½, where a and b are the two perpendicular
diameters. SAHA, TSA, and HNHA doses were chosen
based on published studies HDAC inhibitor [20-22].
In vivo toxicity study
In vivo toxicity assays were performed using BALB/c
nude mice. Six-week-old mice were caged for 1 week for
acclimatization. Each group of 25 mice was injected in-
traperitoneally with SAHA, TSA, or HNHA at a dose of
30 mg/kg per mouse. The animals were monitored regu-
larly for external signs of toxicity or lethality.
Immunohistochemistry
All tissues were fixed in 10% neutral-buffered formalin
and embedded in paraffin wax using standard protocols.D
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A498 
nd cell adhesion assays showed that HNHA induced the greatest
oints indicate mean % of the solvent-treated control. (A, D) and
P < 0.05 vs. Control, **P < 0.01 vs. Control, ***P < 0.005 vs. Control.
Table 1 IC50 (half maximal inhibitory concentration) determination using a cell proliferation assay
Cell line Tissue derived Animal Cell proliferation IC50 (μM)
HNHA TSA SAHA
Caki-1 Kidney: clear cell type renal cell arcinoma Human 20.61 (±0.9) 49.29 (±1.1) 32.14 (±1.1)
A498 Kidney; renal cell carcinoma Human 20.95 (±1.0) 40.19 (±1.4) 33.01 (±1.8)
786-O Kidney; clear cell type renal cell carcinoma Human 23.29 (±1.1) 45. 30 (±1.0) 30.97 (±1.7)
UMRC-3 Kidney; clear cell type renal cell carcinoma Human 32.28 (±1.0) 53.42 (±1.0) 40.13 (±0.7)
Each data point represents the mean of three independent IC50 experiments performed in triplicate by MTT assay. SD, standard deviation.
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trieval was performed in citrate buffer (pH 6), using an
electric pressure cooker set at 120°C for 5 min. Sections
were incubated for 5 min in 3% hydrogen peroxide to
quench endogenous tissue peroxidase. The primary
monoclonal antibody was directed against cytochrome c
(Abcam, Cambridge, UK), and was diluted 1:100withA
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Figure 3 HNHA induced G0/G1 phase arrest and apoptosis in RCC cel
HNHA induced G0/G1 phase arrest and increased the sub-G0 population in
potently induced the expression of cell cycle arrest proteins (p53 and p21)
cyclin D1) and resulted in increased levels of anti-apoptotic (Bax and Apaf-phosphate-buffered saline. All tissue sections were coun-
terstained with hematoxylin, dehydrated, and mounted.
Statistical analysis
Statistical analyses were performed using the GraphPad
Prism software (GraphPad Software Inc., La Jolla, CA,
USA). Immunohistochemistry results were subjected tols. FACS flow cytometry with propidium iodide staining showed that
Caki-1 and A-498 cells (A). Western blotting showed that HNHA
, reduced positive regulators of cell cycle progression (CDK4/6 and
1) proteins in RCC cells (B).
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Values are expressed as means ± SEM. P values < 0.05
were considered to indicate statistical significance.Results
HNHA induced histone H3 acetylation in RCC cells
To investigate the effects of HNHA on histone acetylation
in RCC cells, we exposed Caki-1 and A-498 cells to
HNHA at various doses and then evaluated histone H3
acetylation by Western blotting. Acetylation of histone H3
was induced by HNHA in a dose-dependent manner
(Figure 1A). We also assessed the effects of HNHA on the
acetylation of non-histone proteins using α-tubulin; α-
tubulin acetylation was also increased by HNHA in aA
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Figure 4 HNHA induced caspase-dependent apoptotic death of RCC ce
Caki-1 and A-498 cells (A, B). TUNEL assay of apoptotic cells in Caki-1 and A-4dose-dependent manner (Figure 1A). To determine the
duration of maintenance of histone H3 acetylation by
HNHA, protein levels were evaluated by Western blotting
at 1, 6, 24, 48, and 72 h after HNHA treatment. Histone
H3 acetylation peaked at 1 h after administration of
HNHA and remained stable until 48 h (Figure 2B). These
data show that HNHA can induce stable acetylation of
histone H3, and also non-histone proteins, in RCC cells.HNHA suppressed RCC tumor cell proliferation
To investigate the antitumor effects of HNHA in com-
parison with previously established HDAC inhibitors in
RCC, a cell proliferation assay using SAHA, TSA, and
HNHA and a panel of RCC cell lines was performedB
A
49
8
lls. Immunoblot analysis for Bcl-2, phospho-IκB, and caspases-3 and -7 in
98 cells; TUNEL-positive (apoptotic) cells are indicated (×400) (C).
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had a lower IC50 in all RCC cell lines (Caki-1, A-498,
786-O, UMRC-3) tested. To further characterize the
effects of HNHA on RCC tumor cell viability, we
evaluated Caki-1 and A-498 cells. All HDAC inhibi-
tors (SAHA, TSA and HNHA) reduced the viability of
RCC cells compared to controls. However, HNHA
showed the strongest suppression of cell proliferation
among the HDAC inhibitors (Figure 2A, Caki-1 and D, A-
498); moreover, the suppression of proliferation was dose-
dependent (Figure 2B, Caki-1 and E, A-498). Cell numbers
and adhesion abilities were lower in the HNHA-treated
groups than the control group, and the cells exhibited a
more elongated shape, consistent with the morphological
changes caused by SAHA and TSA treatment (Figure 2C,
Caki-1 and F, A-498).C D
E F
A
Caki-1
B
Caki-1
Figure 5 HNHA induced cytochrome c-dependent, caspase-dependen
Bax level was increased, and cytochrome c release into the cytosol was en
cytochemical staining showed that cytochrome c was translocated and acc
through a cytochrome-c-dependent pathway. (C, D) Western blot analysis aft
into the nucleus after HNHA treatment (E, F).HNHA induced G0/G1 cell cycle arrest in RCC cells
To investigate the effects of HNHA on cell cycle progres-
sion, propidium iodide staining and flow cytometry were
performed after treatment with several HDAC inhibitors,
including HNHA. The HDAC inhibitors induced G0/G1
phase arrest and increased the sub G0 population (p <
0.05), suggesting induction of cell cycle arrest and apoptosis
in RCC (Figure 3A). The data also suggested that HNHA
was the most potent apoptosis inducer of those tested. To
assess pro-apoptotic signaling pathways following treatment
with these drugs, we evaluated the expression of cell-cycle
arrest (p53 and p21) and anti-apoptotic (Bax and Apaf-1)
proteins by Western blotting (Figure 3B). HNHA resulted
in increased levels of the cell-cycle arrest (p53 and p21)
and anti-apoptotic (Bax and Apaf-1) proteins in RCC cells.
Furthermore, HNHA reduced CDK 4, CDK 6 and cyclinA498 
A498 
t apoptotic death in RCCs. Subcellular fractionation showed that the
hanced by HNHA, in Caki-1 (A) and A 498 cells (B). Immunofluorescent
umulated in the nucleus, suggesting that HNHA induced apoptosis
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Figure 6 HNHA exhibited the most potent anti-tumor effects in RCC xenografts. HNHA induced more potent inhibition of tumor progression
than the established HDAC inhibitors and resulted in the greatest prolongation of survival in Caki-1 (A, B) and A-498 (C, D) xenografts. ‘No tumor’
indicates HNHA-, TSA- and SAHA-treated mice without a xenograft in panels (E) and (F). Each group = 10 mice, survival curves for 63 days. Mean body
weights on days 1, 3, 5, 7, 9, 11, 13, 15, 17 and 19 of mice treated with HNHA, TSA and SAHA on Caki-1 (G) and A-498 (H) xenografts (Each group = 10
mice). *P < 0.05 vs. Control, **P < 0.01 vs. Control, ***P < 0.005 vs. Control.
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Figure 7 (See legend on next page.)
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Figure 7 HNHA reduced tumor burden and induced caspase-dependent apoptotic cell death in an in vivo model. Immunoblot analysis for
Bcl-2, phospho-IκB, and caspases-3 and -7 in Caki-1 and A-498 cells (A, B). Cytochrome c protein levels were determined by immunohistochemistry to
decide when to sacrifice the animal (C, D). Negative control slides (IgG control) were treated with isotype-matched IgG. Error bars show SEs (n = 7).
*P < 0.05, vs. control, **P < 0.01, vs. control, ***P < 0.005, vs. control. The MetaMorph 4.6 image-analysis software was used to quantify the
immunostained target protein.
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able to the highest inhibition of viability in RCC cells.HNHA-induced apoptosis of RCC cells was
caspase-dependent
SAHA and TSA induce apoptosis by activating the caspase
pathways in tumor cells. To investigate whether the antitu-
mor effects of HNHA were dependent on pro-apoptotic
signaling pathways, we evaluated Bcl-2 expression and the
activation of caspases-3 and -7 in Caki-1 and A-498 cells
treated with SAHA, TSA, and HNHA by Western blotting
and TUNEL assays. Western blots showed that HNHA
enriched the ‘pro’ form of caspase-3 and induced the cleav-
age of pro-caspase-3 and pro-caspase-7 more potently
than did TSA or SAHA (Figure 4A, B). The TUNEL assay
confirmed that HNHA induced apoptosis in RCC cells
more potently than did TSA or SAHA (Figure 4C). More-
over, HNHA and SAHA abolished Bcl-2 and p-IκB expres-
sion almost completely in RCC cells. These data suggest
that HNHA is the most potent apoptosis inducer of the
compounds tested and exerts this effect via caspase activa-
tion and inhibition of the Bcl-2 pathway in RCC cells.HNHA induced cytochrome c release from mitochondria and
translocation from the cytoplasm to the nucleus in RCC cells
DNA damage induces apoptosis by release of cyto-
chrome c from mitochondria. To assess the mechanisms
of HNHA-induced apoptosis, we next evaluated the
expression of cytochrome c and caspases using immuno-
fluorescence and Western blotting. Subcellular fraction-
ation demonstrated that the HDAC inhibitors activated
the mitochondrial pathway of apoptosis, characterized
by the translocation of Bax (a proapoptotic Bcl-2 pro-
tein) from the cytosol to the mitochondria and the release
of cytochrome c from the mitochondria into the cytosol in
Caki-1 and A-498 cells (Figure 5A, B). Immunofluorescent
cytochemical staining showed that cytochrome c was
translocated and accumulated in the nucleus, suggesting
that HNHA induces apoptosis through a cytochrome-c-
dependent pathway (Figure 5C, D). Western blot analysis
after subcellular fractionation that confirmed cytochrome
c was translocated into the nucleus after HNHA treatment
(Figure 5E, F). In summary, these results suggest that
apoptosis is induced by HNHA through caspase- and
cytochrome-c-dependent pathways in RCC cells.HNHA reduced the tumor burden and improved survival
in RCC xenografts
To investigate the antitumor effect of HNHA in vivo,
we developed subcutaneous RCC xenograft mouse
models using Caki-1 and A-498 cells. SAHA and TSA
showed significant suppression of tumor growth in RCC
xenografts; however, HNHA exhibited greater suppres-
sion of the growth of RCC xenografts (Figure 6A, B).
Also, survival was prolonged significantly by all HDAC
inhibitors, but to a greater extent by HNHA than SAHA
or TSA (Figure 6C, D). No evidence of systemic toxicity
or treatment-related death was found in any group
(Figure 6E, F). There was no significant effect on the body
weight of mice treated with SAHA, TSA and HNHA com-
pared to the control group (Figure 6G, H).HNHA suppressed in vivo tumor growth via
downregulation of Bcl-2 and p-IκB and activation of
caspase in RCC cells
To determine whether the potent antitumor effect of
HNHA in the in vivo animal model was related to the in-
duction of apoptosis, we examined the expression of
apoptosis-related proteins in xenograft tissues harvested
after treatment. All HDAC inhibitors downregulated Bcl-2
expression and activation of IκB, induced the ‘pro’ forms
of caspases-3 and -7, and activated caspases-3 and -7 by
cleavage in Caki-1 and A-498 xenografts (Figure 7A, B).
HNHA showed the most potent inhibition of Bcl-2 and
p-IκB and activation of caspase in RCC cells. To examine
whether the induction of apoptosis was related to cyto-
chrome c release, we performed immunohistochemical
staining for cytochrome c in the harvested xenografts
(Figure 7C, D). Cytochrome c was stained focally in the
cytoplasm in the control group but diffusely throughout
the cytoplasm in the groups treated with HDAC inhibi-
tors. The staining was most intense in the HNHA-treated
xenografts. In summary, these data indicate that HNHA
induced more potent RCC tumor suppression in an ani-
mal model by activation of caspase-dependent apoptotic
signals and cytochrome c release from mitochondria.Discussion
One of the most remarkable advances in RCC treatment
is the therapeutic application of anti-angiogenic therapy
and mTOR inhibitors based on the important role of the
HIF pathway in RCC. Most agents available today for
Park et al. BMC Cancer  (2015) 15:19 Page 11 of 12the treatment of advanced RCC target the von Hippel-
Lindau gene (VHL)/hypoxia-inducible factor (HIF) path-
way [23]. Agents targeting the vascular endothelial growth
factor (VEGF) and/or mammalian target of rapamycin
(mTOR) pathways continue to be the mainstay of treat-
ment for metastatic RCC; however, durable, complete re-
sponses remain the exception. There is a continuing need
for the identification of novel pathways and agents for
treating RCC [24].
Recent progress in understanding the molecular mecha-
nisms in RCC centers on the roles of epigenetic alterations
and transcriptional deregulation. A high-throughput gene
study involving solution capture and sequencing of the
coding exons of 20,000 protein-coding genes identified
new cancer loci, including genes encoding enzymes that
demethylate/methylate key lysine residues in histone H3,
which is implicated in transcriptional control by regulating
chromatin structure [23,25]. Another study found truncat-
ing mutations in the PBRM1 gene, which encodes the
Baf180 protein, a chromatin-targeting subunit of the SWI/
SNF chromatin remodeling complex that has been impli-
cated in multiple chromatin/transcriptionally mediated
processes through interaction with histone H3, in 41% of
RCC cases [26].
Histone modification is now a well-known epigenetic
modification. Among several types of histone modification,
histone deacetylation is deregulated in many cancers. A re-
cent study revealed that HDAC1, HDAC2, and HDAC3
are highly expressed in RCC [16]. Several studies point to
overexpression of class I HDACs, in particular HDAC1, as
a cancer marker associated with a poor prognosis [27].
HDAC inhibitors have been developed to reverse gene si-
lencing by inhibiting HDAC activity and increasing histone
acetylation. These inhibitors function by binding to the
catalytic site of the enzyme. There are four distinct classes
of HDAC inhibitor: short-chain fatty acids (valproic acid
and butyrates), hydroxamic acids (trichostatin A, TSA, and
suberoylanilide hydroxamic acid), cyclic tetrapeptides (tra-
poxin and depsipeptide), and benzamides [28,29].
Preclinical studies have shown the potential of HDAC
inhibitors in the treatment of RCC. Valproic acid (VPA)
altered cell-cycle-regulating proteins, particularly CDK2,
cyclin B, cyclin D3, p21, and Rb, and significantly inhib-
ited the growth of Caki-1 in subcutaneous xenografts,
accompanied by strong accumulation of p21 and Bax in
tissue specimens of VPA-treated animals [30]. Another
HDAC inhibitor, SAHA, reduced the proliferation of
RCC cells and augmented the activity of the mTOR in-
hibitor temsirolimus to induce apoptosis in xenografted
RCC cell lines and depsipeptide-induced apoptosis in
Caki-1, ACHN, and 786O cells, and induced G2 cell
cycle arrest in 769P cells [17,31,32]. However, in contrast
with the promising preclinical results, clinical trials of
the HDAC inhibitors vorinostat and panobinostat haveshown only modest activity in refractory metastatic RCC.
In a phase II study of SAHA (vorinostat) in advanced RCC
patients, SAHA showed disease stabilization in 29% pa-
tients, while a phase II trial of a different HDAC inhibitor,
panobinostat, in patients with refractory metastatic RCC,
failed to show an objective response [33,34]. It is difficult
to evaluate the anti-tumor activity of these HDAC inhibi-
tors for treatment-naïve advanced RCC because all partici-
pants in the study had previously been heavily treated.
Nevertheless, that HDACs exist as targets and HDAC in-
hibitors show anti-tumor activities in RCC, but only mod-
est activity in clinical trials, suggests that more potent
HDAC inhibitors are required to achieve a clinical benefit
in RCC.
In summary, we showed that HNHA had more potent
anti-tumor activity than the established HDAC inhibitors
SAHA and TSA with induction of apoptosis through ex-
pression of Bcl-2 and engagement of the mitochondrial
pathway in RCC cells in vitro and in vivo. HNHA activated
the caspase- and cytochrome-c-dependent apoptotic path-
ways by inducing release of cytochrome c from mitochon-
dria and its translocation into the nucleus in RCC cells. In
our study, Bax was found to be upregulated markedly by
all HDAC inhibitors tested—albeit to a greater degree by
HNHA than SAHA or TSA—in RCC cells. HNHA treat-
ment resulted in the greatest level of cytochrome c release
from mitochondria among the HDAC inhibitors tested.
Taken together, although the precise mechanisms of the
anti-cancer effects of HDAC inhibition should be investi-
gated further, our results suggest that HNHA may be a
potent therapeutic option. The role of HDAC inhibition as
an anti-cancer strategy in RCC should be evaluated using
agents more potent than those tested previously.Conclusions
HNHA has more potent anti-tumor activity than estab-
lished HDAC inhibitors. Its effects are mediated by
caspase-dependent and cytochrome-c-mediated apoptosis
in RCC cells. These results suggest that HNHA may offer
a new therapeutic approach to RCC.
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